Congressional & FDA Testimony
We connect federal and state policymakers to the wisdom on the ground about what women need, where their rights are being threatened, and where we are building momentum.
Featured Testimony
FDA Meeting – Development, authorization and licensure of vaccines to prevent COVID-19
By: Sarah Christopherson COVID-19, FDA Advocacy TestimonyTestimony Delivered to the Vaccines and Related Biological Products Advisory Committee
Congressional Hearing – Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety
By: M. Isabelle Chaudry Congress, Cosmetics, Personal Care Products, Toxic Cosmetics TestimonyTestimony Delivered Before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Hearing “Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety”
FDA Meeting – Emergency Use Authorization of the Johnson & Johnson/Janssen Biotech Inc. COVID-19 Vaccine
By: Sarah Christopherson COVID-19, FDA Advocacy, Vaccine TestimonyTestimony Delivered to the Vaccines and Related Biological Products Advisory Committee
FDA Comments – Possible Emergency Authorization of the Moderna COVID-19 Vaccine
By: Cindy Pearson TestimonyComments submitted to the Vaccines and Related Biological Products Advisory Committee
Explore all TESTIMONY & PUBLIC COMMENT:
Results for:
FDA Meeting – Emergency Use Authorization of the Johnson & Johnson/Janssen Biotech Inc. COVID-19 Vaccine
By: Sarah Christopherson ,COVID-19, FDA Advocacy, Vaccine TestimonyTestimony Delivered to the Vaccines and Related Biological Products Advisory Committee
FDA Comments – Possible Emergency Authorization of the Moderna COVID-19 Vaccine
By: Cindy Pearson TestimonyComments submitted to the Vaccines and Related Biological Products Advisory Committee
FDA Meeting – Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine
By: Sarah Christopherson ,COVID-19, FDA Advocacy TestimonyTestimony Delivered to the Vaccines and Related Biological Products Advisory Committee
FDA Meeting – FDA’s Communications About the Safety of Medical Devices
By: Gabriela Salas TestimonyOral Presentation Delivered to the Center for Devices and Radiological Health Virtual Public Meeting
FDA Meeting – Development, authorization and licensure of vaccines to prevent COVID-19
By: Sarah Christopherson ,COVID-19, FDA Advocacy TestimonyTestimony Delivered to the Vaccines and Related Biological Products Advisory Committee
FDA Comments — Office of Women’s Health Strategic Priorities
By: Sarah Christopherson ,Clinical Trials, FDA Advocacy TestimonyPublic comments urging the FDA's Office of Women’s Health to ensure that women’s needs are represented across FDA and in the agency’s research, education, and public outreach.
Congressional Hearing — The Disproportionate Impact of COVID-19 on Communities of Color
By: M. Isabelle Chaudry ,Black Women, COVID-19, Health Equity, People of Color, Women of Color TestimonyStatement from M. Isabelle Chaudry, Esq., Senior Policy Manager, National Women’s Health Network: House Ways and Means Committee
FDA Meeting – Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc
By: M. Isabelle Chaudry ,FDA Advocacy, Personal Care Products, Talc TestimonyU.S. Food & Drug Administration Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc
Congressional Hearing – Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety
By: M. Isabelle Chaudry ,Congress, Cosmetics, Personal Care Products, Toxic Cosmetics TestimonyTestimony Delivered Before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Hearing “Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety”
FDA Meeting – Agile Transdermal Contraceptive Patch AG200-15
By: Sarah Christopherson ,Birth Control, FDA Advocacy TestimonyTestimony Delivered at the Meeting of the FDA Bone, Reproductive and Urologic Drugs Advisory Committee